Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372084 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02372084 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT02372084, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.
Interventions
- DRUG osilodrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-04-21 |
| Est. Completion | 2016-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372084
The ClinicalTrials.gov registry entry for NCT02372084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which osilodrostat is the first listed.
NCT02372084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372084 about?
NCT02372084 is a clinical study titled "A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function". To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.
What is the current status of trial NCT02372084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-04-21. Estimated completion is 2016-05-19.
What interventions are being tested in trial NCT02372084?
The interventions under investigation include: osilodrostat (DRUG).
Who is sponsoring clinical trial NCT02372084?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.